Granules India – II

I valued Granules back in July post their annual results and found it to be undervalued. I did not invest in it as the margin was not good enough. I kept tabs on it over the last 5 months and this is my valuation of Granules post their Q2 results.

Numbers and Narratives

Granules India is a small pharmaceutical company that primarily makes its revenues from the sale of high volume – low margin generic drugs in the US and around the world. They are also investing into R&D to improve that core business and venture out into niche products. I expect them to be a high growth company in the near term and maintain their industry average margins in that time.

The core numbers that I arrive at based on the story are

  • Compounded revenue growth for next 5 years = 15% (20% TTM)
  • EBIT margin in year 10 = 18% (18% industry average)
  • Initial cost of capital = 10.20%

Valuation

I’ve used the above numbers along with the financial information to compute my DCF valuation for Granules India as seen below.

As you can see, the valuation price came out to ₹341.30, about 10% higher than the last traded price of ₹311.90.

Information


Disclaimer

Leave a comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.